Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE positive about lung cancer drug

  • Comment

Draft guidance has recommended afatinib (Giotrif) as a treatment for locally advanced, or metastatic, non-small-cell lung cancer.

The National Institute for Health and Care Excellence proposed that it be given to patients whose tumours test positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and have not previously received an EGFR-TK inhibitor.

Sir Andrew Dillon

Sir Andrew Dillon

The drug, which is made by Boehringer Ingelheim, works by blocking the signal pathways helping to slow the growth and spread of tumours.

Sir Andrew Dillon, chief executive of NICE, said: “We’ve already recommended two drugs, gefitinib and erlotinib, as options for the first-line treatment for patients with this form of lung cancer and we’re pleased that this draft guidance recommends a further option.”




  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs